Collaborating in more than 150 countries.By clicking on a link below, you may enter a different part of this website, or a website outside of Janssen.com.These sections or websites are governed by their own Legal and Privacy Policies.
Asia Pacific (Regional)
English | Français | Nederlands
Deutsch | Français
Latin America (Regional)
Central America and the Caribbean
Spanish | English
English | Français
Welcome to Janssen Europe, Middle-East and Africa
VISIT JANSSEN GLOBAL
In June 2017, Actelion became part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Actelion,...
Cardiovascular and metabolic diseases are a major threat to life for adults, accounting for millions of deaths...
We have a strong history of delivering biological medicines for immunological diseases and we continue to build a...
Neuroscience We are laser-focused on delivering new medicines to treat brain disorders such as schizophrenia, Alzheimer...
World demand for antibiotics remains high due to escalating resistance and the increased risk of serious infections in...
At Janssen, we are working to change expectations of what a cancer diagnosis means
We are actively developing treatments for our patients in six important therapeutic areas of healthcare. Our solutions...
While illness never sleeps and our industry and employees constantly strive for innovations that transform how diseases...
We think of the world as our laboratory, and we look for innovation wherever it exists
In response to what would become the worst Ebola outbreak in history, Janssen accelerated the development programme for...